Uterine contractility: vaginal administration of the beta-adrenergic agonist, terbutaline. Evidence of direct vagina-to-uterus transport

Détails

ID Serval
serval:BIB_3C618F91A7B5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Uterine contractility: vaginal administration of the beta-adrenergic agonist, terbutaline. Evidence of direct vagina-to-uterus transport
Périodique
Annals of the New York Academy of Sciences
Auteur(s)
Bulletti  C., de Ziegler  D., de Moustier  B., Polli  V., Bolelli  G., Franceschetti  F., Flamigni  C.
ISSN
0077-8923
Statut éditorial
Publié
Date de publication
09/2001
Peer-reviewed
Oui
Volume
943
Pages
163-71
Notes
In Vitro
Journal Article --- Old month value: Sep
Résumé
Spontaneous uterine contractility during the menstrual cycle is required for menstruation, gamete transport, and, most likely, embryo nidation. Abnormal uterine contractility has been linked to dysmenorrhea, a condition associated with painful uterine cramping. Based on previous studies with progesterone, we have postulated the existence of a portal system that is responsible for some degree of direct vagina-to-uterus transport of administered compounds (i.e., the "first uterine pass effect"). It is possible that treatment with uterorelaxing substances, particularly beta-adrenergic agonists, may alleviate the uterine discomfort that accompanies dysmenorrhea. However, side effects encountered with oral administration of beta-agonists limit their utility. Alternatively, vaginal delivery of beta-agonists could solve this dilemma by enhancing their efficacy and reducing side effects. Therefore, in the current study we used hysterectomy specimens and an in vitro uterine perfusion system to test the vagina-to-uterus transport of [3H]terbutaline, a well-known beta-agonist. With the use of autoradiographic and scintillation counting techniques, our results clearly show progressive diffusion of labeled terbutaline from the rim of vaginal tissue through the uterus during the first 12 hours of perfusion. This indicates that uterine targeting of terbutaline can be accomplished through vaginal administration, suggesting a new therapeutic modality in women's health care.
Mots-clé
Administration, Intravaginal Adrenergic beta-Agonists/administration & dosage/*pharmacokinetics Adult Autoradiography Biological Transport Female Humans Terbutaline/administration & dosage/*pharmacokinetics Uterine Contraction/*drug effects Uterus/*metabolism Vagina/*metabolism
Pubmed
Web of science
Création de la notice
28/02/2008 12:36
Dernière modification de la notice
20/08/2019 14:32
Données d'usage